These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 34118951

  • 1. Single-cell RNA sequencing reveals the mechanism of sonodynamic therapy combined with a RAS inhibitor in the setting of hepatocellular carcinoma.
    Wu B, Yuan Y, Liu J, Shang H, Dong J, Liang X, Wang D, Chen Y, Wang C, Zhou Y, Jing H, Cheng W.
    J Nanobiotechnology; 2021 Jun 12; 19(1):177. PubMed ID: 34118951
    [Abstract] [Full Text] [Related]

  • 2. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
    Charette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I, Stärkel P.
    Mol Cancer; 2010 Sep 22; 9():256. PubMed ID: 20860815
    [Abstract] [Full Text] [Related]

  • 3. RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma.
    Jiang C, Song T, Li J, Ao F, Gong X, Lu Y, Zhang C, Chen L, Liu Y, He H, Huang O.
    Mol Neurobiol; 2017 Jan 22; 54(1):779-787. PubMed ID: 27021020
    [Abstract] [Full Text] [Related]

  • 4. Functional inhibition of Ras by S-trans,trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice.
    George J, Afek A, Keren P, Herz I, Goldberg I, Haklai R, Kloog Y, Keren G.
    Circulation; 2002 May 21; 105(20):2416-22. PubMed ID: 12021230
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes.
    Aizman E, Mor A, Levy A, George J, Kloog Y.
    Oncotarget; 2012 Feb 21; 3(2):144-57. PubMed ID: 22323550
    [Abstract] [Full Text] [Related]

  • 7. Ras antagonist inhibits growth and chemosensitizes human epithelial ovarian cancer cells.
    Beiner ME, Niv H, Haklai R, Elad-Sfadia G, Kloog Y, Ben-Baruch G.
    Int J Gynecol Cancer; 2006 Feb 21; 16 Suppl 1():200-6. PubMed ID: 16515591
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sinoporphyrin sodium based sonodynamic therapy induces anti-tumor effects in hepatocellular carcinoma and activates p53/caspase 3 axis.
    Li E, Sun Y, Lv G, Li Y, Zhang Z, Hu Z, Cao W.
    Int J Biochem Cell Biol; 2019 Aug 21; 113():104-114. PubMed ID: 30660690
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice.
    Weisz B, Giehl K, Gana-Weisz M, Egozi Y, Ben-Baruch G, Marciano D, Gierschik P, Kloog Y.
    Oncogene; 1999 Apr 22; 18(16):2579-88. PubMed ID: 10353601
    [Abstract] [Full Text] [Related]

  • 13. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
    Haklai R, Elad-Sfadia G, Egozi Y, Kloog Y.
    Cancer Chemother Pharmacol; 2008 Jan 22; 61(1):89-96. PubMed ID: 17909812
    [Abstract] [Full Text] [Related]

  • 14. Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models.
    Borbath I, Stärkel P.
    Acta Gastroenterol Belg; 2011 Mar 22; 74(1):34-44. PubMed ID: 21563652
    [Abstract] [Full Text] [Related]

  • 15. Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc.
    Yaari-Stark S, Shaked M, Nevo-Caspi Y, Jacob-Hircsh J, Shamir R, Rechavi G, Kloog Y.
    Int J Cancer; 2010 May 15; 126(10):2268-81. PubMed ID: 19998334
    [Abstract] [Full Text] [Related]

  • 16. Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling.
    Barkan B, Kloog Y, Ehrlich M.
    Mol Cancer Ther; 2011 Aug 15; 10(8):1317-26. PubMed ID: 21632464
    [Abstract] [Full Text] [Related]

  • 17. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
    Barkan B, Starinsky S, Friedman E, Stein R, Kloog Y.
    Clin Cancer Res; 2006 Sep 15; 12(18):5533-42. PubMed ID: 17000690
    [Abstract] [Full Text] [Related]

  • 18. Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives.
    Wu L, Pang Y, Qin G, Xi G, Wu S, Wang X, Chen T.
    PLoS One; 2017 Sep 15; 12(2):e0171840. PubMed ID: 28182780
    [Abstract] [Full Text] [Related]

  • 19. Sonosensitizer Nanoplatforms Augmented Sonodynamic Therapy-Sensitizing Shikonin-Induced Necroptosis Against Hepatocellular Carcinoma.
    Tian H, Shang H, Chen Y, Wu B, Wang C, Wang X, Cheng W.
    Int J Nanomedicine; 2023 Sep 15; 18():7079-7092. PubMed ID: 38050474
    [Abstract] [Full Text] [Related]

  • 20. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats.
    Reif S, Weis B, Aeed H, Gana-Weis M, Zaidel L, Avni Y, Romanelli RG, Pinzani M, Kloog Y, Bruck R.
    J Hepatol; 1999 Dec 15; 31(6):1053-61. PubMed ID: 10604579
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.